MedPath

Effects of dietary protein distribution and resistance exercise training on muscle health in older adults

Not Applicable
Completed
Conditions
Sarcopenia
Musculoskeletal Diseases
Registration Number
ISRCTN64199452
Lead Sponsor
niversity of Birmingham
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
12
Inclusion Criteria

1. Aged 65 years or over
2. Female
3. Ambulatory (with or without walking aids)

Exclusion Criteria

1. Already engaging in regular exercise (at least twice a week)
2. History of myocardial infarction within previous 2 years
3. Cardiac illness: moderate/ severe aortic stenosis, acute pericarditis, acute myocarditis, aneurysm, severe angina,
4. Clinically significant valvular disease, uncontrolled dysrhythmia, claudication within the previous 10 years
5. Thrombophlebitis or pulmonary embolus within the previous 2 years
6. History of cerebrovascular disease (CVA or TIA) within the previous 2 years
7. Treatment with anticoagulants (Warfarin, rivaroxaban, apixaban, dabigatran) and antiplatelets (dipyridamole, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa antagonists). Nb. those regularly taking aspirin will be asked to stop for 3 days prior to biopsies and restart the day after
8. Acute febrile illness within the previous 3 months
9. Severe airflow obstruction
10. Uncontrolled metabolic disease (e.g., thyroid disease or cancer)
11. Significant emotional distress, psychotic illness or depression within the previous 2 years
12. Lower limb fracture sustained within the previous 2 years; upper limb fracture within the previous 6 months; non arthroscopic lower limb joint surgery within the previous 2 years
13. Any reason for loss of mobility for greater than 1 week in the previous 2 months or greater than 2 weeks in the previous 6 months
14. Resting systolic pressure >200 mmHg or resting diastolic pressure >100mmHg
15. Poorly controlled atrial fibrillation
16. Poor (chronic) pain control
17. Moderate/ severe cognitive impairment (MMSE <23)
18. Renal impairment (Stage 4 or 5)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath